Arix Bioscience (ARIX)


ARIX Share PerformanceMore

52 week high218.00 17/02/17
52 week low167.50 16/08/17
52 week change 0.00 (0.00%)
4 week volume355,257 23/01/18
price date1518797173

Latest NewsMore

Arix outlines 2017 achievements and 2018 objectives

In a letter from the CEO to shareholders, Arix Bioscience has confirmed that during 2017 the Company has directed a sub...

CEO Letter to Shareholders

RNS Number: 0023B Arix Bioscience Plc 04 January 2018 CEO Letter to Shareholders LONDON, 4 January 2018: As 2018 gets underway, I would like to reflect on Arix Bioscience plc 's ( LSE: ARIX) ("Arix Bioscience" or "Arix" ) first year as a public company and offer some thoughts on the year ahead. We started 2017 with the ambition of building a business with t...

Voting Rights and Capital: Month End Disclosure

RNS Number: 8259A Arix Bioscience Plc 03 January 2018 3 January 2018 Arix Bioscience plc Voting Rights and Capital: Month End Disclosure Pursuant to Disclosure and Transparency Rule 5.6.1: As at 31 December 2017, the issued share capital of Arix Bioscience plc comprised 96,153,090 ordinary shares of 0.00001 each and 49,671 non-voting C Shares of 1.00 each. There ...

Issue of Ordinary Shares, TVR, PDMR Shareholding

RNS Number: 1503A Arix Bioscience Plc 22 December 2017 22 December 2017 Arix Bioscience plc Issue of Ordinary Shares, Total Voting Rights and Director/PDMR Shareholding Notifications Arix Bioscience plc (the "Company") announces that it has allotted New Ordinary Shares to two non-executive directors, in accordance with the compensation agreed at their ...

Arix Bioscience co-leads $30m financing for Aura Biosciences

Arix Bioscience has co-led a $30 million series C financing round for Aura Biosciences. Aura is developing a new class of th...

Arix co-leads $30m financing for Aura Biosciences

RNS Number: 0060A Arix Bioscience Plc 21 December 2017 Arix Bioscience co-leads $30 million financing for Aura Biosciences Funding to advance development of Aura's novel treatment to selectively destroy cancer cells; lead candidate AU-011 currently in Phase 1b/2 study to treat ocular melanoma, an orphan indication LONDON, 21 December 2017: Arix Bioscienc...

Arix leads $30m financing for Atox Bio

Arix Bioscience has led an oversubscribed $30 million series F financing round for Atox Bio. Atox Bio is a late stage clinica...

Arix Bioscience leads $30m financing for Atox Bio

RNS Number: 2209Y Arix Bioscience Plc 04 December 2017 Arix Bioscience leads $30 million financing for Atox Bio Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical development in necrotising soft tissue infections Arix achieves target of 12 Group Businesses by the end of 2017, suc...

Fundamental DataMore

Dividend yield0 %

Latest discussion posts More

  • Re: welcome

    Blimey, what's going on? Some negative news out there? IPO oversubscribed and some major holdings - it should be heading the other way. JC
  • Re: welcome

    Been a bit of a dog so far
  • Re: welcome

    I could not make sense as to what this company is about. Is it similar to Shire which funds R&D through other Biotechs, but it does not have its owns labs?

Users' HoldingsMore

Users who hold Arix Bioscience also hold..

Codes & Symbols


Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account